# Guardant Health Inc. (GH) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $161.41, market value $21.7 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Guardant Health Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 18.3×**. Each dollar of revenue is priced at 18.3×, a level that requires very high margins or very fast growth to justify.
- **Free-cash-flow yield: -1.1%** (5-yr avg -7.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -39.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -42.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: 419.2%**. A 419.2% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: -36.2%**. Return on all capital, debt included, is -36.2%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -22.5%**. Each dollar of assets produces -22.5% of profit.

## Growth
- **Revenue growth (1 yr): 32.9%** (3-yr 29.8%/yr, 5-yr 27.9%/yr). Revenue grew 32.9% over the last year, against 27.9% a year compounded over five years.
- **EPS growth (1 yr): 6.7%**. Earnings per share rose 6.7%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: net cash**. Guardant Health Inc. holds more cash than debt.
- **Altman Z-score: 5.85**. A Z-score of 5.85 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Guardant Health Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (24 analysts). 24 analysts cover Guardant Health Inc.; the consensus is strong_buy, with an average price target of $194.29 (+20% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 163.1%** (YTD 58.0%, 3-mo 28.5%). The shares are up 163.1% over twelve months including dividends.
- **From 52-week high: -8.6%** (202.3% above the low). Trading 9% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 0.91** (volatility 58%). Beta of 0.91 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GH · Page: https://foliofundamentals.com/stocks/gh

Not investment advice.